Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. - Test2 - elhamkhani - TriplyDB

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

http://www.wikidata.org/entity/Q34642090

about

Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer Novel therapeutic targets for pancreatic cancer Keystone symposium: the role of microenvironment in tumor induction and progression, Banff, Canada, 5-10 February 2005 Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment Genetics and biology of pancreatic ductal adenocarcinoma Nonproliferative and Proliferative Lesions of the Gastrointestinal Tract, Pancreas and Salivary Glands of the Rat and Mouse Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up Weaknesses and Pitfalls of Using Mice and Rats in Cancer Chemoprevention Studies GEMMs as preclinical models for testing pancreatic cancer therapies Single and Multiple Gene Manipulations in Mouse Models of Human Cancer Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles Mouse models of pancreatic cancer Critical role of NF-κB in pancreatic cancer Rebuilding cancer metastasis in the mouse Molecular mechanism underlying lymphatic metastasis in pancreatic cancer Genetically engineered mouse models of pancreatic adenocarcinoma Mouse models for studying angiogenesis and lymphangiogenesis in cancer Pancreatic ductal cells in development, regeneration, and neoplasia Innovations in proteomic profiling of cancers: alternative splice variants as a new class of cancer biomarker candidates and bridging of proteomics with structural biology Oncolytic viral therapy for pancreatic cancer: current research and future directions The pancreas cancer microenvironment Acute pancreatitis accelerates initiation and progression to pancreatic cancer in mice expressing oncogenic Kras in the nestin cell lineage r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing.Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer Somatic mutations in exocrine pancreatic tumors: association with patient survival Genetic factors affecting patient responses to pancreatic cancer treatment Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer Anti-pancreatic cancer deliverables from sea: first-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algae mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma EMT and dissemination precede pancreatic tumor formation Obesity and cancer pathogenesis.Ras history: The saga continues.

P2860

Q21144653-A6D4F95B-2EEC-4246-B7BD-E03FA0A180F1 Q24337345-230ABE89-4C19-4268-A6B9-B511F3887DC1 Q24564267-4F74B704-5336-4437-99E0-3CA0BF28BCA2 Q24810275-5BF41F27-01B7-4D42-ACA6-EA8E259AC45A Q26740619-B59CD71F-E669-416C-81DF-E53E6BA7A646 Q26765438-A9DF5629-7BAE-4F1C-B80F-963ECD3C9906 Q26766096-89E126E6-C1BB-4434-BEDB-EFAAD6ECF953 Q26780372-9A4D9213-3412-433D-8C19-28D8262E4D5F Q26781102-440AE002-E285-49F8-9B12-E396BD59F4FF Q26781848-FE4E3F68-6A60-4BD7-A9E7-47033E633006 Q26783920-73AB364D-C699-4F6D-8B74-888D1B5D652E Q26828959-184DFF4C-939C-45E2-8C16-691AD4C66375 Q26860574-23BA2800-AE3A-41A9-876E-FCBABF2324A9 Q26864198-76235C96-3CB3-41B0-A649-91FD08B6CCE2 Q26864450-62EEB9F3-ECE4-4450-9B2C-E17DB644E952 Q26999345-60EE1410-C779-4B16-A1FA-B726F5050DA7 Q27002973-71F2CA7A-E334-4738-9434-C43DB857979D Q27003898-6DDFC9EB-2CF1-4979-BE5D-FAEB51646F6A Q27006729-C79F4126-2BF7-439D-8753-2E454D328083 Q27011213-E33ABDB0-592F-4866-A5BD-BE9832439A57 Q27011439-3E6A3DA1-09DD-4037-A8D1-D45E3672C474 Q27026705-27F4F432-8D48-4D25-B23C-FF7E5FC57594 Q27312357-7DF9484D-90BD-46E2-80F5-0BC7F93F0A42 Q27321768-90A3FF84-CC1D-425F-9520-1EE5FD4CAFD3 Q27322787-77948ABC-1C90-488B-9E09-8E2BE9E7EC97 Q27334957-A808E093-1321-4EA6-8B1D-841A315A60F4 Q27852155-2172F425-C443-4B3D-A83F-68D9AD551798 Q28075293-16DCFF1B-5BF6-4D94-9406-9835F12E7B88 Q28083091-221AE12A-E549-4D08-929E-21AF3784B01F Q28287448-DB94978F-38A9-41CD-BECB-B2A7AE9E7ABE Q28289209-41607CA5-0EF6-4180-BBBB-BACA507C3923 Q28391921-CEB6CD4A-4526-49CF-85BE-19F0F54077BE Q28478427-D2A4BECB-BC56-4F0F-A83E-22938031AC07 Q28478758-08FB0235-1C27-4E82-B4F7-D2102C9E40F3 Q28486199-5F2E0815-DBEF-45C0-9AD8-31395ACEAD58 Q28512979-AB2CFDB6-377E-43C4-A04B-4191856EFF9F Q28534618-41B359EB-A393-4EF4-9181-E2673255AD3C Q29615854-D22613DC-C646-446B-B7D3-8E62C92FCEE6 Q30361298-F6C3EE97-B291-41E1-BCC7-71C95BBCF152 Q30404024-A0BC984F-FA41-4CC1-A64C-49020155913D

P2860

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

http://www.wikidata.org/entity/Q34642090

description

2003 nî lūn-bûn

@nan

2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Activated Kras and Ink4a/Arf d ...... creatic ductal adenocarcinoma.

@ast

Activated Kras and Ink4a/Arf d ...... creatic ductal adenocarcinoma.

@en

Activated Kras and Ink4a/Arf d ...... creatic ductal adenocarcinoma.

@nl

type

label

Activated Kras and Ink4a/Arf d ...... creatic ductal adenocarcinoma.

@ast

Activated Kras and Ink4a/Arf d ...... creatic ductal adenocarcinoma.

@en

Activated Kras and Ink4a/Arf d ...... creatic ductal adenocarcinoma.

@nl

prefLabel

Activated Kras and Ink4a/Arf d ...... creatic ductal adenocarcinoma.

@ast

Activated Kras and Ink4a/Arf d ...... creatic ductal adenocarcinoma.

@en

Activated Kras and Ink4a/Arf d ...... creatic ductal adenocarcinoma.

@nl

P1433

Q34642090-377CB2F1-901A-4779-A551-9EA831C0C713

P1476

Q34642090-6851784B-A188-435F-A042-719D62112234

P2093

Q34642090-01898B32-A08E-4AF8-ACF6-FF0DDA7BBD07

Q34642090-0FB8FB80-6486-4EC9-A079-5C743A30CD4F

Q34642090-3A7907BA-3D97-4C63-A742-CEAD26649AEF

Q34642090-6C3E6FE7-34F0-4AF8-87D9-9907F3C7F05B

Q34642090-AAF6FE4F-3436-42BF-8BB7-7052ACB91052

Q34642090-BC2D0637-F700-42FC-BE40-05D6E1B2B3F3

Q34642090-D82895DF-3601-4F3E-A575-C65E65B6BDE7

P2860

Q34642090-00A3966D-9EBE-43E7-B46B-99F64E0C5BAF

Q34642090-0242C6B1-9BED-4493-87AD-0A7C819BB4C7

Q34642090-03E1C0F2-4249-4366-8E20-E244891BFD49

Q34642090-05325F33-CCF7-4683-9D1A-BA3918569E42

Q34642090-09A3F2C1-0B3C-4A37-9A40-B43DCDAE5BDE

Q34642090-0A17F46F-AB42-43A8-8694-59E8EE291F08

Q34642090-0C4B2EB6-9E40-418F-8708-3FC2C9841C2C

Q34642090-0C6D6CBF-D0E9-44F6-9F7D-E443B92CE48A

Q34642090-1228818B-C84E-48D3-9D55-F03F0E48E82F

Q34642090-17B19B21-96A2-46BA-8EED-9BF67B1ED63E

P304

Q34642090-16EBAF82-8960-4582-BB7C-454AE35633C9

P31

Q34642090-E2DC609B-961D-4604-9BE1-87CB95263F18

P356

Q34642090-A1F145E3-030F-4E10-92EA-68F0F6D127FA

P433

Q34642090-704080F3-18FC-4816-AC12-4D3B2B8F8F3E

P478

Q34642090-F5E72610-EF79-4646-BC17-B67E429EB03A

P50

Q34642090-0FD1CC52-A537-4087-83A9-F3D902070807

Q34642090-925C005D-667F-4D63-A627-A9B60A3B3F15

P577

Q34642090-EB7CF1B6-2655-4AF5-B62F-213654EA5465

P5875

Q34642090-F7915145-A9D0-412D-8711-31CEAFED1DC6

P698

Q34642090-59C415FC-BCCD-453C-8595-83C02E6F526B

P921

Q34642090-F63DDE49-0A2F-4D18-9EA0-8FB2A1162292

P932

Q34642090-ABDFFBD5-D252-42E7-809E-C61A9477344E

P356

P1433

Genes & Development

P1476

Activated Kras and Ink4a/Arf d ...... creatic ductal adenocarcinoma.

@en

P2093

Andrew J Aguirre

http://www.w3.org/2001/XMLSchema#string

James Horner

http://www.w3.org/2001/XMLSchema#string

Lyle Lopez

http://www.w3.org/2001/XMLSchema#string

Manisha Sinha

http://www.w3.org/2001/XMLSchema#string

Mark S Redston

http://www.w3.org/2001/XMLSchema#string

Nabeel Bardeesy

http://www.w3.org/2001/XMLSchema#string

Ronald A DePinho

http://www.w3.org/2001/XMLSchema#string

P2860

The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

What is the origin of pancreatic adenocarcinoma?

Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest

Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors

Modulation of rat pancreatic acinoductal transdifferentiation and expression of PDX-1 in vitro

Efficient in vivo manipulation of mouse genomic sequences at the zygote stage

P304

3112-3126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1101/GAD.1158703

http://www.w3.org/2001/XMLSchema#string

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Nabeel Bardeesy

P577

2003-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8954819

http://www.w3.org/2001/XMLSchema#string

P698

14681207

http://www.w3.org/2001/XMLSchema#string

P921

P932

305262

http://www.w3.org/2001/XMLSchema#string